Decloxizine Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as decloxizine hydrochloride under the manufacturer model designation DCLX-VET/API-7. The product is not a finished veterinary medicinal product; it is an active pharmaceutical ingredient intended solely for incorporation into authorized formulations by facilities operating under 21 CFR 211 or equivalent national GMP codes. The release specification covers identification by infrared absorption and HPLC retention time, assay, related substances, residual solvents, elemental impurities, loss on drying, residue on ignition, polymorphic identity, and particle-size distribution. The base chemical class is a first-generation piperazine H1-receptor antagonist. For tableting and premix work, the manufacturer distinguishes injection grade DCLX-VET/INJ, tablet/capsule grade DCLX-VET/TBL, and premix/powder grade DCLX-VET/PREMIX. These designations differ chiefly in particle-size D90, bulk density, microbial limits, and endotoxin control; the chemical identity and assay criterion remain identical.

What limits aqueous injectable formulation pH for decloxizine hydrochloride?

Injectable formulation development for this API is governed by the salt’s pH-dependent solubility and the need to avoid precipitation during terminal sterilization. Published data for the specific pH-solubility profile of decloxizine hydrochloride in veterinary parenteral vehicles is limited; development studies should include pH-solubility profiles over pH 2.0–7.0 in citrate and phosphate buffers at 25 °C and 4 °C. The injectable grade is released with endotoxin ≤0.15 EU/mg and total aerobic microbial count ≤10² CFU/g, assessed per Ph. Eur. 2.6.14 and 2.6.12. Terminal sterilization compatibility should be confirmed with a 0.22 µm PVDF filter when the drug concentration is 0.5% w/v or lower; higher concentrations require filter adsorption testing before filling. Organic impurities from degradation in heat-sterilized solutions are monitored using a stability-indicating HPLC method with photodiode array detection at 230 nm. Total unspecified impurities should remain ≤0.10% after 121 °C for 15 min only if the formulation pH is maintained at 4.0–5.0. Precipitation and pH drift above 6.0 are known operational boundaries. Phosphate-buffered vehicles without tonicity adjustment may increase injection-site irritation and should be replaced with isotonic sodium chloride or dextrose.

For capsules, the API is milled to a D90 target of ≤75 µm and often pre-blended with colloidal silicon dioxide at 0.25% w/w to reduce electrostatic charge. In low-dose capsule formulations, direct filling on dosator machines is sensitive to powder flow; a conditioned bulk density of 0.45 g/mL–0.60 g/mL and a Hausner ratio of 1.15–1.35 are typically specified for reproducible plug formation. For oral solutions, the hydrochloride salt is dissolved in a co-solvent system containing propylene glycol and buffered vehicle. The finished solution must be protected from light and stored in amber glass or HDPE containers. Published data for long-term photostability of this veterinary API in aqueous admixture is limited; forced degradation under ICH Q1B conditions should be performed on the final pack.

Premix homogeneity, sieve fractions, and flow function for low-dose antihistamine feeds

In medicated feed premix manufacture, the particle-size distribution of the premix grade is broader to reduce segregation after dilution with ground corn or soybean meal carriers. The release specification for DCLX-VET/PREMIX sets D10 ≥10 µm, D50 55 µm–95 µm, and D90 ≤150 µm by laser diffraction according to ISO 13320:2020. Bulk density is controlled within 0.55 g/mL–0.75 g/mL because higher-density particles can settle through rations during conveying. Field observations on screw conveyors with a 45° incline show that segregation becomes visually detectable above a bulk-density difference of 0.18 g/mL between API and carrier. Milling on a pin mill with classifier gap 300 µm and rotor tip speed 85 m/s reproduces the target distribution, but batch-to-batch variance in D90 increases when incoming crystal habit changes from plate-like to needle-like. Micronization may raise amorphous content, and recrystallization during storage can bridge screens and reduce flow. The premix grade is therefore double-bagged in low-moisture-transmission polyethylene liners and sampled after 24 h equilibration at 40% RH to avoid static charge effects on sieve analysis.

When lactose monohydrate is replaced in direct-compression tablet formulations

Direct-compression tablets containing low-dose decloxizine hydrochloride are commonly formulated with lactose monohydrate, microcrystalline cellulose, and croscarmellose sodium. If lactose is replaced with dicalcium phosphate dehydrate or isomalt for ration compatibility, blend segregation and tablet hardness can shift because the API’s electrostatic adhesion to polar carriers changes. Production-scale observations on a 10-station rotary tablet press show that compressional force must be increased by 15%–20% when dicalcium phosphate is used. Tablet tensile strength at a given force remains 1.1 MPa–1.8 MPa for lactose-based blends and falls below 0.8 MPa for some phosphate-based blends without a binder. Content uniformity is assessed according to Ph. Eur. 2.9.40 or USP <905>; a target formulation with 5 mg label claim requires a process capability index of at least 1.33 for individual mass and drug content. Residual moisture above 5.0% in wet-granulated tablets reduces stability and promotes hydrolysis of the piperazine salt. Granule drying with a fluid-bed dryer at inlet air temperature 55 °C–65 °C until loss on drying 1.0%–2.0% is recommended.

Comparator APIs and the basis for grade selection in veterinary multi-source dossiers

The product differs from hydroxyzine hydrochloride and chlorpheniramine maleate in several pharmaceutical and regulatory respects. Decloxizine hydrochloride is supplied as an unformulated veterinary-grade API with explicit particle-size and endotoxin release controls, whereas many comparator antihistamines are marketed as human finished products with differing impurity profiles. Pharmacopoeial and dossier-level distinctions are also relevant. Hydroxyzine hydrochloride is an approved human antihistamine with a terminal hydroxyethoxy substituent; the molecule is converted to cetirizine by hepatic oxidation in several species. Decloxizine carries a 3-methylbenzyl substituent at the piperazine nitrogen and is not chemically identical to the cetirizine precursor. Chlorpheniramine maleate belongs to the propylamine class rather than the piperazine class, and its maleate salt introduces a different acid counterion that can affect excipient compatibility in dry blends. For veterinary multi-source submissions, the API supplier must provide a route of synthesis, residual solvent declaration, and nitrosamine risk assessment. This is the principal difference from technical-grade chemical availability, not the pharmacological class alone.

Decloxizine hydrochloride assay, related substances, and mass balance under a veterinary CEP framework

Release of the API is executed against a specification derived from current Ph. Eur. general chapters and the manufacturer’s master production record. Assay is determined by anhydrous, solvent-free potentiometric titration with perchloric acid and expressed as 99.0%–101.0% on the dried basis. Related substances are quantified by reversed-phase HPLC using a C18 column with 5 µm particles, 250 mm length, and mobile phase containing acetonitrile and phosphate buffer at pH 3.0. Individual unspecified impurities are limited to ≤0.10%; total impurities are limited to ≤0.30%. The API is stored in airtight containers at 15 °C–25 °C; re-test period is 36 months from date of manufacture when kept below 60% RH. Residual solvent levels are controlled by headspace gas chromatography per Ph. Eur. 2.4.24; ethanol, methanol, and acetonitrile are targeted to not exceed 0.5%, 0.3%, and 0.041% respectively unless justified. Elemental impurities are controlled by ICP-MS on the basis of risk assessment for oral and injectable veterinary routes under ICH Q3D; arsenic, cadmium, mercury, and lead are limited to ≤1.5 µg/g, ≤0.5 µg/g, ≤0.5 µg/g, and ≤0.5 µg/g respectively in the oral grade, with tighter parenteral limits when required by the marketing authorization.

Wet-granulation processing of the tablet/capsule grade is carried out in a high-shear granulator with impeller tip speed 4 m/s–6 m/s and a binder solution of povidone K30 at 2.0%–4.0% w/w in purified water. Granules are milled through a 0.8 mm conical screen and dried to residual moisture 1.0%–2.0% before lubrication with magnesium stearate 0.5% w/w. The final blend is compressed on a rotary press to tablet hardness 45 N–75 N; friability is controlled below 1.0% according to Ph. Eur. 2.9.7. For granules used in multidose oral solutions reconstituted with water, sodium lauryl sulfate below 0.1% w/v is used to avoid precipitation; however, concentrations above 0.3% w/v may suppress assay recovery of the hydrochloride salt by ion-pair extraction. These operational boundaries are written into the batch manufacturing record to prevent out-of-specification results caused by wetting and particle aggregation.

Technical-grade decloxizine not produced under veterinary GMP can exhibit variable polymorph ratio, residual solvent carryover, and microbial counts above 10³ CFU/g. The veterinary API is packed in 25 kg or 50 kg drums with low-density polyethylene liners, labeled with the model designation and assigned a certificate of analysis. Each batch is accompanied by certificate of origin, IR spectrum, HPLC chromatograms, and stability statement. The product differs from use as a compounding chemical by providing a documented particle-size and impurity file suitable for inclusion in a veterinary marketing authorization. Without such documentation, a formulator would be required to re-qualify the raw material under 21 CFR 211.84 sampling and testing responsibilities. For injectable production, the certificate of analysis for endotoxin and microbial limits is an essential release criterion; published data for particulate burden in reconstituted veterinary solutions is limited, so the applicant must validate filtration and filling conditions with the specific container closure system.

Occupational exposure during weighing and milling is managed with local exhaust ventilation and respiratory protection when dust is generated. The API is a histamine H1 antagonist with potential sedative properties. No harmonized occupational exposure limit exists for veterinary compounding with this substance, so the manufacturer uses an in-house airborne dust limit of 0.1 mg/m³ for non-routine operations. Cleaning validation studies use swab limits based on a health-based permitted daily exposure calculation. Cross-contamination with beta-lactam antibiotics or hormonal products is controlled by dedicated facilities. The API is not compatible with oxidizers or strong alkaline solutions, which accelerate degradation to N-oxide and piperazine ring-opened impurities.